FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295817178> ?p ?o ?g. }

• W4295817178 endingPage "S870" @default.
• W4295817178 startingPage "S869" @default.
• W4295817178 abstract "In HIMALAYA (NCT03298451), a single, high priming dose of T plus D (STRIDE) significantly improved overall survival (OS) vs sorafenib (S), and D was noninferior to S in uHCC (Abou-Alfa et al. J Clin Oncol 2022;40(suppl 4). Abs 379). Viral aetiology is associated with hepatic impairment in HCC development, and may influence immunotherapy activity. Thus, we analysed the impact of viral aetiology on clinical outcomes. This exploratory analysis assessed STRIDE, D and S in patients (pts) with HBV (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA), HCV or nonviral/other (NV) aetiology. OS hazard ratios (HRs) were calculated using a Cox proportional hazards model. As subsets were not sized for formal comparisons, no multiplicity adjustments were made. A post hoc multivariate analysis was used to identify chance imbalances in key prognostic factors that may bias estimated treatment effects. Baseline demographic and disease characteristics were similar across treatment arms in the HBV and NV subsets. However, in the HCV group, multivariate analysis identified imbalances in two prognostic variables: extrahepatic spread (EHS; more frequent for STRIDE than S) and ALBI (score ≥2 more frequent for STRIDE and D than S). OS and progression-free survival were improved with STRIDE vs S in the HBV and NV groups, but not in the HCV group (Table). Using a stratified Cox proportional hazards model to account for imbalances in EHS and ALBI in the HCV subset, OS HRs favoured STRIDE vs S. OS HRs continued to favour STRIDE when adjusting for EHS and ALBI in the other groups. Results for D vs S showed similar trends to those for STRIDE vs S (Table).Table: 714POSHR vs S; 95% CIOSCox-stratifieda HR vs S; 95% CIObjective response, %Disease control rate, %Median time to response, monthsMedian duration of response, monthsHBVSTRIDE n=1220.64; 0.48–0.860.64; 0.47–0.8621.359.01.925.7D n=1190.78; 0.58–1.040.78; 0.58–1.0414.349.61.99.5S n=1195.048.72.817.0HCVSTRIDE n=1101.06; 0.76–1.490.89; 0.63–1.2535.565.53.613.5D n=1071.05; 0.75–1.480.93; 0.66–1.3122.457.92.012.9S n=1049.670.27.315.7NVSTRIDE n=1610.74; 0.57–0.950.77; 0.59–1.00b18.057.12.113.2D n=1630.82; 0.64–1.050.80; 0.62–1.0319.056.43.713.8S n=1666.063.33.76.0aAdjusted for EHS and ALBI. bn=160; one pt with missing ALBI score excluded. Open table in a new tab aAdjusted for EHS and ALBI. bn=160; one pt with missing ALBI score excluded. In HIMALAYA, OS favoured STRIDE vs S (HR <1) for all aetiologies when subsets were adjusted for prognostic factor imbalances in the HCV cohort; similar trends were observed with D vs S across subsets. These results confirm the benefits of STRIDE and D in pts with uHCC, irrespective of underlying aetiology." @default.
• W4295817178 created "2022-09-15" @default.
• W4295817178 creator A5000168988 @default.
• W4295817178 creator A5017702124 @default.
• W4295817178 creator A5017964678 @default.
• W4295817178 creator A5024563189 @default.
• W4295817178 creator A5031469873 @default.
• W4295817178 creator A5033329129 @default.
• W4295817178 creator A5038721807 @default.
• W4295817178 creator A5043987479 @default.
• W4295817178 creator A5044971260 @default.
• W4295817178 creator A5048752147 @default.
• W4295817178 creator A5055479902 @default.
• W4295817178 creator A5056197140 @default.
• W4295817178 creator A5056787992 @default.
• W4295817178 creator A5061515387 @default.
• W4295817178 creator A5062054307 @default.
• W4295817178 creator A5063436506 @default.
• W4295817178 creator A5065283428 @default.
• W4295817178 creator A5076456783 @default.
• W4295817178 creator A5079819925 @default.
• W4295817178 creator A5085766415 @default.
• W4295817178 date "2022-09-01" @default.
• W4295817178 modified "2023-09-27" @default.
• W4295817178 title "714P Impact of viral aetiology in the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)" @default.
• W4295817178 doi "https://doi.org/10.1016/j.annonc.2022.07.838" @default.
• W4295817178 hasPublicationYear "2022" @default.
• W4295817178 type Work @default.
• W4295817178 citedByCount "3" @default.
• W4295817178 countsByYear W42958171782023 @default.
• W4295817178 crossrefType "journal-article" @default.
• W4295817178 hasAuthorship W4295817178A5000168988 @default.
• W4295817178 hasAuthorship W4295817178A5017702124 @default.
• W4295817178 hasAuthorship W4295817178A5017964678 @default.
• W4295817178 hasAuthorship W4295817178A5024563189 @default.
• W4295817178 hasAuthorship W4295817178A5031469873 @default.
• W4295817178 hasAuthorship W4295817178A5033329129 @default.
• W4295817178 hasAuthorship W4295817178A5038721807 @default.
• W4295817178 hasAuthorship W4295817178A5043987479 @default.
• W4295817178 hasAuthorship W4295817178A5044971260 @default.
• W4295817178 hasAuthorship W4295817178A5048752147 @default.
• W4295817178 hasAuthorship W4295817178A5055479902 @default.
• W4295817178 hasAuthorship W4295817178A5056197140 @default.
• W4295817178 hasAuthorship W4295817178A5056787992 @default.
• W4295817178 hasAuthorship W4295817178A5061515387 @default.
• W4295817178 hasAuthorship W4295817178A5062054307 @default.
• W4295817178 hasAuthorship W4295817178A5063436506 @default.
• W4295817178 hasAuthorship W4295817178A5065283428 @default.
• W4295817178 hasAuthorship W4295817178A5076456783 @default.
• W4295817178 hasAuthorship W4295817178A5079819925 @default.
• W4295817178 hasAuthorship W4295817178A5085766415 @default.
• W4295817178 hasConcept C121608353 @default.
• W4295817178 hasConcept C126322002 @default.
• W4295817178 hasConcept C137627325 @default.
• W4295817178 hasConcept C143998085 @default.
• W4295817178 hasConcept C203014093 @default.
• W4295817178 hasConcept C207103383 @default.
• W4295817178 hasConcept C2522874641 @default.
• W4295817178 hasConcept C2777410769 @default.
• W4295817178 hasConcept C2777701055 @default.
• W4295817178 hasConcept C2777742743 @default.
• W4295817178 hasConcept C2778019345 @default.
• W4295817178 hasConcept C2778650287 @default.
• W4295817178 hasConcept C2780030458 @default.
• W4295817178 hasConcept C2780593183 @default.
• W4295817178 hasConcept C2781433595 @default.
• W4295817178 hasConcept C38180746 @default.
• W4295817178 hasConcept C44249647 @default.
• W4295817178 hasConcept C50382708 @default.
• W4295817178 hasConcept C71924100 @default.
• W4295817178 hasConcept C90924648 @default.
• W4295817178 hasConceptScore W4295817178C121608353 @default.
• W4295817178 hasConceptScore W4295817178C126322002 @default.
• W4295817178 hasConceptScore W4295817178C137627325 @default.
• W4295817178 hasConceptScore W4295817178C143998085 @default.
• W4295817178 hasConceptScore W4295817178C203014093 @default.
• W4295817178 hasConceptScore W4295817178C207103383 @default.
• W4295817178 hasConceptScore W4295817178C2522874641 @default.
• W4295817178 hasConceptScore W4295817178C2777410769 @default.
• W4295817178 hasConceptScore W4295817178C2777701055 @default.
• W4295817178 hasConceptScore W4295817178C2777742743 @default.
• W4295817178 hasConceptScore W4295817178C2778019345 @default.
• W4295817178 hasConceptScore W4295817178C2778650287 @default.
• W4295817178 hasConceptScore W4295817178C2780030458 @default.
• W4295817178 hasConceptScore W4295817178C2780593183 @default.
• W4295817178 hasConceptScore W4295817178C2781433595 @default.
• W4295817178 hasConceptScore W4295817178C38180746 @default.
• W4295817178 hasConceptScore W4295817178C44249647 @default.
• W4295817178 hasConceptScore W4295817178C50382708 @default.
• W4295817178 hasConceptScore W4295817178C71924100 @default.
• W4295817178 hasConceptScore W4295817178C90924648 @default.
• W4295817178 hasLocation W42958171781 @default.
• W4295817178 hasOpenAccess W4295817178 @default.
• W4295817178 hasPrimaryLocation W42958171781 @default.
• W4295817178 hasRelatedWork W125090411 @default.
• W4295817178 hasRelatedWork W1975434185 @default.
• W4295817178 hasRelatedWork W1992278374 @default.
• W4295817178 hasRelatedWork W2120574916 @default.

• next